ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2758

Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders?

J. Antonio Avina-Zubieta1, Andrew Chow2, Philip Baer3, John Kelsall4, Proton Rahman5, Jacqueline Stewart6, Boulos Haraoui7, Michel Zummer8, Emmanouil Rampakakis9, Eliofotisti Psaradellis10, Francois Nantel11, Karina Maslova12, Cathy Tkaczyk13, Brendan Osborne13 and Allen J Lehman12, 1Arthritis Research Canada, Richmond, BC, Canada, 2Credit Valley Rheumatology, Mississauga, ON, Canada, 3Independent Rheumatology Practice, Scarborough, ON, Canada, 4Rheumatology, University of British Columbia, Vancouver, BC, Canada, 5Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, 6Penticton Regional Hospital, Penticton, BC, Canada, 7University of Montreal, Montreal, QC, Canada, 8Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, 9JSS Medical Research, St-Laurent, QC, Canada, 10JSS Medical Research, Montreal, QC, Canada, 1119 Green belt Dr, Janssen Inc., Toronto, ON, Canada, 12Janssen Inc., Toronto, ON, Canada, 13Medical Affairs, Janssen Inc., Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biologic agents, Clinical Response, psoriatic arthritis and registry

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Minimal disease activity (MDA) is now considered an objective target which is more attainable in psoriatic arthritis (PsA) compared to remission (DAS28 <2.6) which is more difficult to achieve and maintain. The criteria for MDA encompass different aspects of this distinct and heterogeneous disease. The aim of this analysis was to assess which unmet criteria were more common among patients who achieved MDA based on patient reported outcomes (PROs) in a real-world, routine clinical care setting in Canada.

Methods:  BioTRAC is an ongoing, prospective registry of patients initiating treatment for rheumatoid arthritis (RA), ankylosing spondylitis (AS), or psoriatic arthritis (PsA) with infliximab (IFX) or golimumab (GLM). Eligible patients for this analysis included PsA patients treated with IFX or GLM between 2005 and 2015. MDA was defined as the fulfillment of ≥5 of the following criteria: TJC28≤1, SJC28≤1, PASI≤1, pain (VAS) ≤15 mm, PtGA (VAS) ≤20 mm, HAQ≤0.5, tender entheseal points ≤1.

Results: A total of 223 PsA patients (51.4% male) were included with a mean (SD) age of 49.8 (11.1) years and disease duration since diagnosis of 5.4 (6.3) years. MDA was achieved by 11.7%, 43.5%, and 44.8% at baseline, 6 months and 12 months of treatment, respectively. The most commonly unmet MDA criteria in patients who achieved 5/7 criteria was patient-reported pain (69.2%), PtGA (48.7%), and HAQ (20.5%). The mean (SD) for these disease parameters were 31.8 (13.5) mm for pain, 39.3 (10.9) mm for PtGA and 0.95 (0.46) for HAQ. Furthermore, in these patients the most prevalent combination in unmet criteria was pain+PtGA with 38.5% followed by PASI+pain with 12.8%. In patients who achieved 6/7 MDA criteria, the most commonly unmet criteria included PASI with 21.9%, pain with 18.8% and HAQ with 18.8%. The mean (SD) for these disease parameters were 3.7 (2.1) for PASI, 22.8 (7.9) mm for pain and 0.75 (0.08) for HAQ.

Conclusion: The current analysis has shown that by 6 months of treatment almost 50% of patients achieved MDA. Among patients who achieved 5/7 criteria the most commonly unmet criteria in patients who achieved MDA are PROs including pain, PtGA and HAQ-DI. These results highlight the difference in the perception of disease activity by physicians and patients and in the relative importance placed on specific disease aspects.


Disclosure: J. A. Avina-Zubieta, Janssen Inc., 5; A. Chow, Janssen Inc., 5; P. Baer, Janssen Inc., 5; J. Kelsall, Janssen Inc., 5; P. Rahman, Janssen Inc., 5; J. Stewart, Janssen Inc., 5; B. Haraoui, Janssen Inc., 5; M. Zummer, Janssen Pharmaceutica Product, L.P., 5; E. Rampakakis, employee of JSS Medical Research, 3; E. Psaradellis, employee of JSS Medical Research, 3; F. Nantel, Employee of Janssen Inc., 3; K. Maslova, Employee of Janssen Inc., 3; C. Tkaczyk, Employee of Janssen Inc., 3; B. Osborne, Employee of Janssen Inc., 3; A. J. Lehman, Employee of Janssen Inc., 3.

To cite this abstract in AMA style:

Avina-Zubieta JA, Chow A, Baer P, Kelsall J, Rahman P, Stewart J, Haraoui B, Zummer M, Rampakakis E, Psaradellis E, Nantel F, Maslova K, Tkaczyk C, Osborne B, Lehman AJ. Minimal Disease Activity Among Psoriatic Arthritis Patients in Canada: Which Unmet Criteria Are More Prevalent Among Responders? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/minimal-disease-activity-among-psoriatic-arthritis-patients-in-canada-which-unmet-criteria-are-more-prevalent-among-responders/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/minimal-disease-activity-among-psoriatic-arthritis-patients-in-canada-which-unmet-criteria-are-more-prevalent-among-responders/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology